Assessment of Pancreatic Physiological and Pathological Characteristics Based on Spectral CT

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorYu Shi

About this trial

Patients who visited our hospital for various reasons from January 2024, underwent CT scans involving the pancreas, and were eligible for spectral post-processing reconstruction were included in the study. This research collected spectral CT data related to the pancreas at different phases, as well as physiological and pathological states for these patients. Quantitative analysis was conducted on post-processed data under different physiological and pathological states, including parameters such as pancreatic iodine uptake features, attenuation interval slopes, and extracellular volume size. In conjunction with general patient status, biochemical tests, and postoperative pathological results, the study aimed to identify correlations between parameters, develop models, and conduct research by comparing traditional CT data, which could be matched with spectral CT from the PACS database since its establishment.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Previous pancreatic surgery with incomplete pancreatic tissue.

Severe systemic diseases that result in severe organ dysfunction

Excessive pancreatic atrophy or other reasons cannot accurately delineate ROI

Trial population

Age, sex, body mass index (BMI) and grading, diabetes history, smoking history, hypertension. Patients with primary pancreatic disease who undergo surgery or biopsy according to clinical routine during their hospitalization in our hospital and obtain pathological results are included.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • The post-processing generated after scanning is converted into energy spectrum image data (SBI)

    Other intervention

    It will not open special sequences for patients, will not increase the cost of diagnosis and treatment, will not increase radiation exposure during enhanced CT scanning, and will not affect the normal diagnosis and treatment process of patients throughout the process.

Treatment groups

1,500 Participants
are divided into 2 treatment groups
Group A: test group1 intervention
Group B: control group1 intervention

Trial outcomes

Primary outcomes

1

spectral imaging data(SBI)

Using Philips Intellispace Portal software to reconstruct spectral imaging data images

Time frame
21/3/2025
2

ROI area(mm2)

Using Philips Intellispace Portal software to delineate the Region of Interest (ROI)

Time frame
21/3/2025

Secondary outcomes

1

single-energy CT value

Measure the single-energy CT value(Hu)

Time frame
21/3/2025

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Yu Shi

Lead sponsor

Shengjing Hospital

Sponsor institution